Ivabradina Stada

Ivabradine, the active ingredient in Ivabradina Stada, is a If channel inhibitor presented as a tablet for oral use. It lowers heart rate by selective inhibition of the funny current in the sinoatrial node, and is used in chronic stable angina and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers global.

Ivabradina Stada (ivabradine) is used in cardiovascular conditions where heart‑rate reduction is beneficial. - Chronic stable angina: reduces myocardial oxygen demand by lowering heart rate, improving exercise tolerance. - Heart failure with reduced ejection fraction: decreases heart rate, contributing to improved ventricular remodeling and reduced hospitalization risk.

Ivabradina Stada may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate lower than intended. - Headache.

Serious or Rare Side Effects: - Atrial fibrillation. - Severe bradyarrhythmias. - Allergic reactions (rash, angioedema).

When prescribing Ivabradina Stada, clinicians should consider several precautionary measures to ensure safe use. - Dose titration: adjust gradually based on resting heart rate and clinical response. - Concomitant beta‑blockers: monitor for excessive bradycardia when combined. - CYP3A4 inhibitors: avoid strong inhibitors or reduce dose. - Visual symptoms: discontinue if persistent luminous phenomena occur. - Pregnancy and lactation: use only if benefits outweigh potential risks (category unknown). - Store at ambient temperature: keep below 25 °C, protect from moisture in original packaging.

Ivabradina Stada can interact with other medicines, influencing heart rate or drug metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase ivabradine exposure. - Concomitant use with other heart‑rate lowering agents (e.g., beta‑blockers, digoxin) leading to severe bradycardia. - AV‑node blocking drugs (e.g., verapamil, diltiazem): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Antihypertensives: monitor blood pressure and heart rate. - Diuretics in heart‑failure patients: watch for electrolyte shifts affecting cardiac conduction.